Biomea Fusion Inc

Biomea Fusion Inc. is a privately held biopharmaceutical company headquartered in Redwood City, California. With a team of 86 employees, the company focuses on the discovery and development of novel therapeutics. Biomea Fusion specializes in developing covalent small molecules, a unique class of synthetic compounds that form a permanent bond with their target proteins. These covalent drugs offer several advantages over traditional non-covalent drugs, including greater target selectivity, reduced drug exposure, and the potential for more profound and lasting treatment effects. The company's proprietary FUSION™ System platform leverages its expertise in covalent binding chemistry to advance a pipeline of promising covalent therapies. Their lead product candidate, BMF-219, is a potent and selective inhibitor of MENIN, a protein implicated in cancer signaling pathways. Biomea Fusion aims to utilize its platform to develop covalent treatments for other significant oncogenic drivers, ultimately becoming a leading developer of covalent small molecules in the fight against various cancers. Website: biomeafusion.com